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pancreatic cancer. Such stents are usually inserted
Abstract- The ability to safely and effectively deliver high percutaneously under radiological guidance. Stents comprise
dosages of drugs to specific sites in the human body is a tube made of metal or polymer, in a wide range of
fundamental to the advancement of drug delivery research. physiologically appropriate diameters and lengths [1-3].
Drugs with proven effectiveness under in vitro investigation General stent design varies in the number of
often reach a major roadblock under in vivo testing due to a intersections and interstrut area, the in-strut configuration,
lack of an effective delivery strategy. In addition, many clinical ante metlo to-artery rat The two differet expanson
scenarios require delivery of agents that are therapeutic at the and the metal-to-artery ratio. The two different expansion
desired delivery point, but otherwise systemically toxic. This principles for stents are balloon-expansion and self-
paper proposes a method for targeted drug delivery by expansion, and the design types can be categorized into five
applying high magnetic field gradients within the body to an types: ring, tubular, multi-design, coil, and mesh [1-3].
injected superparamagnetic colloidal fluid carrying a drug, Stents have been routinely used over the last thirteen years
without relying on magnetic coils held external to the body to in percutaneous transluminal coronary angioplasty (PTCA),
provide the force. The experimental flow model presented a procedure for the treatment of severe, symptomatic
gives insight into the use of magnetic carriers for site-specific coronary stenosis [I].delivery of therapeutic agents.
Keywords- drug delivery, magnetic targeting, stent B. Restenosis
I. INTRODUCTION In-stent restenosis (the re-closing of the vessel) remains
a major limitation, particularly in coronary stenting.
The intention of this research is to provide both the Restenosis is generally considered a local vascular
method and the devices for capturing drug, cells, or other manifestation of the biological response to injury. The injury
therapeutic agents attached to, or encapsulated within, as a result of catheter insertion consists of denudation of the
colloidal magnetic particles, magnetic liposomes, or intima (endothelium) and stretching of the media (smooth
ferrofluids, at selected sites in a subject. The method and muscle). The wound-healing reaction consists of an
devices are based on using two independent sources of inflammatory phase, a granulation phase, and a remodeling
magnetic field. One is a source for producing strong, but phase. The inflammation is characterized by growth factor
highly localized magnetic field gradients to pull the and platelet activation, the granulation by smooth muscle
magnetized drug carriers toward the selected site within the cell and fibroblast migration and proliferation into the
subject. The other is a source of relatively uniform, but far injured area, and the remodeling phase by proteoglycan and
reaching magnetic field needed to magnetize the drug collagen synthesis, replacing early fibronectin as the major
carriers deep within the subject. component of extracellular matrix [1-2].
The combination of these two magnetic sources allows Coronary stents comprise mechanical scaffolding that
for optimization of the capture efficiency of drug at locally almost completely eliminates recoil and remodeling.
selected sites within the human body. These magnetic field However, neo-intimal growth or proliferation is still a
sources and methods for targeted agent delivery are useful in problem. Neo-intimal proliferation occurs principally at the
preventive medicine, and treatment of injury and disease, site of the primary lesion within the first 6 months after
particularly in applications requiring repeatable and highly implantation, a major checkpoint for patient health post-
concentrated dosing to the tissue surrounding the device surgery [19]. Neo-intima forms during the first week after
without systemic levels of drug toxicity being introduced to PTCA and the progress is well under way after 4 weeks,
the rest of the body. with continued progression over the following months [2]
This neo-intima is an accumulation of smooth muscle cells
A. Stent Background within a proteoglycan matrix that narrows the previously
enlarged lumen. Its formation is triggered by a series of
Stents are commonly used in a variety of biomedical molecular events including leukocyte infiltration, platelet
applications. For example, stents are routinely implanted in activation, smooth muscle cell expansion, extracellular
patients to keep blood vessels open in the coronary arteries, matrix elaboration, and re-endothelializationl [19].
to keep the esophagus from closing due to strictures of
cancer, to keep the ureters open for maintenance of kidney
drainage, and to keep the bile duct open in patients with
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C. Current Treatment Options fields that have strong magnetic field gradients is very
difficult to accomplish with a single source.
There are several treatment options for restenosis in
practice or under investigation. Local drug delivery E. Proposed Design
provides limited systemic release, thereby reducing the risk
of systemic toxicity [1-3]. Techniques for local drug A model for inducing highly localized phase
delivery that have been described include, but are not transformations at defined locations in the vascular system
limited to, direct coating of the stent with drug, coating of by applying 1) external uniform magnetic fields to an
the stent with a drug-containing biodegradable polymer, and injected superparamagnetic colloidal fluid for the purpose of
hydrogel/drug coating. Biodegradable stents have also been magnetization and 2) using implants with patterned
described [1-3]. magnetic material to create high magnetic field gradients
Problems with these technologies, include damage to was described [22]. The use of these magnetizable implants
the polymer layer during implantation (causing portions to in drug delivery was also described previously by the
break off and cause clot formation), the inability to deliver authors [17].
effective concentrations, one-time dosage limitations, and, The proposed design provides a magnetizable implant,
in the case of biodegradable stents, mechanical compromise. preferably a stent, for targeting of magnetic agents to a
An additional concern with the polymer-coated drug-eluting selected site of implantation of the magnetizable implant in
stents is limitation of the growth of the cell layer necessary a subject through the creation of high field gradients as well
to cover the stent and prevent the bare metal from coming in as independent means for creating relatively uniform
long contact with the blood, thereby leading to clot magnetic field for magnetizing the magnetic agents. The
formation [19]. two magnetic sources are independently produced in order
Recently the FDA has approved the TAXUS Tm Express to improve capture efficiency and uniformity of captured
2TM Coronary Stent (Boston Scientific, Boston, MA) which coating, as well as to allow for miniaturization of the
releases the drug paclitaxel, and in early 2003 the implant.
CYPHERTNI Sirolimus-eluting Coronary Stent (Cordis,
Miami, FL) was approved. The U.S. Food and Drug
Administration (FDA) has announced that the agency is II. METHODOLOGY
warning physicians about blood clots and other side effects
associated with the Cypher stent, manufactured by Cordis To determine the legitimacy of the idea of successful of
Corporation, a subsidiary of Johnson & Johnson. The device capture magnetic colloid by an implant in the cardiovascular
has been linked to more than 60 deaths and 290 cases of system, multiple computational models were developed. The
thrombosis (Issued by the FDA on October 29, 2003). focus was on a limiting-case scenario, to determine the
latitude of the technology. The first model designed was
D. Magnetically Tar-geted Drug Delivern based around capture of particles in flow onto a placed
'anchored' particle, as seen in the literature [17]. The
In general, methods and devices proposed in the past to mathematics and logic used for these models were the main
deliver magnetizable drug or agent-containing magnetic influence on the idea of a magnetically segmented stent or
carriers to specific locations in the body rely on a single implant, which have also been modeled. The idea of high,
source of magnetic field to both magnetize the carriers and localized magnetic field gradients is present in both designs,
to pull them by magnetic force to the specific location [4-8]. but accomplished in slightly different manners. Results of
These single magnetic fields for attracting magnetically computational modeling provided adequate starting points
susceptible therapeutic agents can be applied by sources for design of in vitro experimental flow models for testing
external to the body, or by an internal implant.. This single the functionality and effectiveness of magnetic particle
source capture method is at odds with the underlying capture at high flow rate. A project-specific flow chamber
physics of magnetic particle capture, which depends on the was designed by the authors and machined at Drexel
simultaneous imposition of very strong far-reaching University.
magnetic fields and strong spatial magnetic field gradients.
The purpose of the far-reaching field is to increase the A. Flow Chamber Componenlts
magnetic moment of individual drug-containing particles in
the vicinity of the field to the point of magnetic saturation. 1) Materials: A parallel plate flow chamber (PPFC) was
Far-penetrating fields are most typically generated with selected as the best system for applying a laminar flow of
large magnetic sources. However, the force on a particles to a magnetically patterned chip or mesh contained
magnetized particle also depends on the production of within the chamber. The PPFC to be used consists of three
strong magnetic field gradients, which are most easily main layers: a 4" glass wafer with aImagnetic islandlpattern,
generated with very small magnetic sources. Thus, the a layer of poly(dimethyl siloxane) (PDMS) with a cut-out
ability to simultaneously produce far-penetrating magnetic channel, and a 6mm thick abrasion-resistant cast acrylic
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coverpiece. The cover-piece contains two reservoirs (flow
in / flow out) that connect to the pump and the waste Vacuum
receptacle, respectively. In addition there is one vacuum Flow In
connection, which feeds a milled out loop around the Channel
circumference of the piece. This top piece mainly serves to Reserirs Magnetic Mesh
assure correct parallel plate flow, and to seal the top of the F Out
channel firmly to the PDMS layer. FbwOut
The PDMS layer itself is glued atop of a glass wafer
using a thinly applied micro-layer of PDMS, and then as
mentioned is held to the top coverpiece by vacuum. This
method for attaching the PDMS layer has been tested for
stability, endurance, leakage, as well as its ability to
withstand sterilization procedures and has been successful in
all tests. At the end of the channel, a 2 x 2 cm magnetically
electroplated stainless steel mesh is also attached by a thin
layer of PDMS at the end of the actual channel space. Al
description of the preparation and design of the mesh is
included in section B. A diagram of the flow-setup can be
seen in the Figure 1. A variable flow chemical pump Fig I a, I b, Ic. I a shows an overhead view diagram of the chamber with
(Fisher Scientific) draws in solution containing the magnetic magnetic mesh fixed to the channel floor. lb shows an up close view of a
particles and outputs the particles into the mouth of the connected chamber. Ic shows the complete experimental setup with pump,
PPFC. Flow chamber output is released into a waste bottle. chamber, and catch beaker. The setup is aligned over a magnetization coil,
2) Design parameters: Although in the model the and under a Leica microscope for imaging of captured particles.
variable parameter is often the vessel diameter, since the B MagneticMesh Preparation
focus here is on a flow chamber scenario the
characterization will be somewhat different. The design of To simulate a stent-like surface as a plane instead of a
the flow chamber is based on an average sized coronary circular cross-section, stainless steel wire mesh (wire
artery of diameter 3mm. The parameters of the channel in diameter 140mm, square strut spacing at 400im) was
the flow chamber are Height: 2r, Width: '8r, Patter Width electroplated with Cobalt-Nickel alloy at a thickness of14r (2r clearance on each side), and Pattern Length: 2cm, approximately 5gm. This material was chosen to combine
where r is the radius of the average coronary artery: 1.5mm. the strong magnetic properties of Cobalt with the plating
The goal in designing the pattern dimensions was to uniformity of Nickel while reducing the stress on the plated
simulate an 'unrolled' stent (of diameter 3mm and length material with additives such as Saccharin and NaCl. This
2cm) and to continue with the limiting-case scenario combination allows for the creation of a coating layer that
analysis, channel height was set at 2r instead of r in order to
' > ~~~~~~~~~~~canbend d flex without cracking or detaching from thehave the maximum flow velocity occurring in the center of mesh, which is critical for use in stents [20]. Using
the channel. Since each wafer/PDMS-gasket combination is information from Myung's work a bath with higher Cobalt
single use, numerous other configurations are possible. content was used to create a harder magnetic material [21].
In addition, the pattern is aligned towards the end of the Electrodeposition was performed in a 2.5cm by 2.5cm
channel, to ensure many channel diameters worth of by 1.25cm flow cell with continual circulation of bath
distance from the entering reservoir to minimize entrance solution from a reservoir heated to 55 degrees Celsius that
effects at the pattern itself, and to hence obtain steady was agitated by gentle bubbling. A Princeton Applied
parallel plate flow. It is important to note that while the Research 363 potentiostat provided an -800mV voltage with
actual channel itself is around 4cm in length, the full cutout respect to an Ag/Cl reference electrode giving a plating ratelength in the PDMS is 6.5 cm, allowing for space at either of approximately one micron per minute. This resulted in
end of the channel at which the reservoir feeds or empties strongly coatings that have a brilliant aspect, smooth
the channel. surfaces and are unaffected by flexing of the mesh.
The reservoir dimensions are the same at the entrance A scanning electron microscopy (SEM) image of the
and exit, and are sized at approximately 5 times the cross- used mesh can be seen in Figure 2
sectional area of the flow channel to ensure appropriate flow
parameters and speed in the channel itself. As calculated
from resting blood flow rates in the coronary artery of 1.25
ml/sec, an approximately 5.0 cm/s flow velocity for the
channel will used in the experiments (which can be
increased or decreased without modification of the flow
chamber itself, and adjusted for different channel heights).
r
_ S = l = _ = mesh, assuring all capture occurs under flow. In each case,a measured 150 Gauss uniform field was applied, in order to
magnetize the particles for capture by the magnetized mesh.
E. Data Analysis
After experiments were complete, all imaging was
conducted fluorescently, in some cases with an additional
white light used for backlighting. All results presented here
are based solely on qualitative analysis. Other flow
experiments involve magnetic patterning of islands directly
onto the wafer itself. Magnetic patterning of islands of glass
Fig. 2. SEM image of a woven, stainless steel mesh electroplated with wafers is accomplished with the use of photolithography and
Cobalt-Nickel alloy for provision of strong magnetic field gradients metal deposition chambers in the University of Pennsylvania
C. Particle preparation clean room facilities in the micro-fabrication laboratory.
In these cases data analysis will be performed first by
Particles obtained for the first flow experiments are imaging under fluorescent microscope by counting of
superparamagnetic polystyrene particles (about 20% by individual particles for experiments at extremely low
weight magnetite), which are about twice the density of particle concentrations, average intensity of fluorescence
water. The beads are obtained from Spherotech, and are over particular areas, distribution of fluorescence along the
2jim in diameter, and nile red fluorescent. Additional length and width of the pattern, and statistical analysis of
experiments have just been performed with 350nm diameter these variables from one experiment to another. Capture
red fluorescent biodegradable magnetic nanoparticles.. relationships between flow velocity, particle size, particle
From the original particle solution, data on concentration, and channel size must be established for each
approximately how many particles are present in a pattern, inter-related between patterns, and ultimately the
"perfectly" suspended solution is available, and can be used capture efficiency of each pattern will be compared.
to estimate how many particles are introduced into the flow For the experiments presented here, the limitations of
chamber. In each experiment the particles were diluted 1:5 the three dimensional structure directed analysis to be purely
from their original concentration (108 beads/ml for 2 gim qualitative with the intent of determining the capability of
diameter, 101 beads/ml for 350 nm diameter). The capture of magnetic particles onto the magnetically plated
fluorescence of the particles is necessary for identification mesh at various particle sizes under high flow.
of particle capture on a magnetic surface for both qualitative
and quantitative analysis. III. REsuLTs
D. Flow Experiments A. Flow Experimiient Results
Of numerous conducted experiments, presented here are
data from one set of experiments from each of the two listed Magnetically plated mesh had excellent capture success.
particle sizes, each at the same flow velocity of Figure 3 shows two characteristic images of captured 2am
approximately 5 cm/s (adjusted from channel parameters diameter superparamagnetic particles, No images are
and volumetric flow output from the flow pump). These presented from control experiments, as no particles were
two flow experiments were conducted in phosphate buffered brought down in either control scenario.
saline. In each case, a set of two control experiments were
performed: flow of non-magnetic particles across a magnetic
mesh, and flow of magnetic particles across a non-magnetic
mesh.
The flow chamber was placed on the microscope stand
just above a power supply controlled magnetic coil. The
chamber was connected to vacuum, flow in from the pump,
and flow out to the waste beaker. After vacuum sealing the
chamber, a volume of saline was introduced to wet the
channel and flush all air bubbles out. At this point all of the Fig 3. Images of captured 2im magnetic particles on electroplated mesh,
particle dilution (in 10 ml) was introduced in one passage captured at 5 cm/s flow velocity in parallel plate flow. (Left) shows high
through the chamber, followed by a 50 ml volume of saline. accumulations of particles at the edge of the mesh, where large gradients
The purpose of the flushing is to prevent any part of the accumulate. (Right) shows extremely well spread coverage by captured
particle solution from being present at rest over the magnetic particles in a characteristic image consistent with the majority of the mesh.
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models have been designed to predict capture of 1-10
particles from varying starting points, by "islands" of
ferromagnetic material, oriented along an implant in a
channel (to simulate an implant scenario).
In all magnetic drug delivery systems, the magnet
serves two purposes; first, to magnetize the drug, and
secondly to provide magnetic field gradients to capture the
drug. Although large magnets held near or implanted in the
body provide strong magnetic fields to magnetize the drug,
Fig 4. Images of captured 350 nm magnetic particles on electroplated thes lrge magnetscnern ldu wamagnetic field
mesh, captured at 5 cm/s flow velocity in parallel plate flow. (Left) shows these large magnets mherently produce weak magnetic field
extremely well spread coverage by captured particles in a characteristic gradients. Micron-sized magnets provide very strong
image consistent with the majority of the mesh. (Right) shows high magnetic field gradients, however their fields are short-
accumulations of particles at the edge of the mesh, where large gradients range and they may not by themselves efficiently magnetize
accumulate.
the drug.
This magnetic drug delivery system is novel in that the
steps of magnetizing the drug and providing the magnetic
field gradients to capture the drug are accomplished
separately. By using micron-sized magnetic implants in
combination with long-range magnetic fields, it is possible
to both magnetize the drug and create strong magnetic field
gradients for more efficient capture and localization of the
Fig. 5. SEM images of magnetic mesh wire intersections. (Left) shows drug.
mesh unexposed to 21m magnetic particles. (Right) shows mesh successful It may be possible to accomplish both of these steps
in capture of 2jim magnetic particles,
simultaneously in a single implant. One goal is to attempt to
Magnetically plated mesh also had success in capture particles on a magnetic pattern without first
capture of 350nm diameter biodegradable magnetizing the particles with an external field, but so far it
superparamagnetic particles. Figure 4 shows characteristic has been demonstrated that the presence of a 100-300 Gauss,
images of captured particles from these flow experiments. reasonably uniform magnetic field will be sufficient in
Again, no control images are presented. Some perspective magnetizing the particles for capture by the implant-
is limited by the field of view due to the weaving produced gradients. Magnetic material can be applied to a
arrangement of the wires in the mesh. stent or other implant so as not to interfere with the normal
Figure 5 shows SEM images of magnetic mesh with and function of the device. Thus it is possible to add an
without captured 2jim diameter superparamagnetic particles. additional drug-delivering capability to cardiovascular
SEM imaayes were taken in order to gain better .E i implants. In addition, superparamagnetic and weakly
understanding of whether particles were accumulating ferromagnetic implants are typically more biocompatible, as
significantly at the wire intersection points on the mesh. It they are composed of magnetite and other FDA approved
can be seen below that they are well spread across the entire
surface of the mesh, even in the corners of intersections, magneticmateals.Theoretical modeling, physical flow experiments, and
flow experiments in the presence of a cellular boundary
IV. DISCUSSION layer, should provide the relationships and theoretical basis
for magnetic/magnetizable implant design. This can be
The ability to capture magnetic particles in flow has accomplished by analyzing the relationships between
been studied extensively in the past. Friendlaender and co- parameters of the magnetic pattern (size, orientation,
authors have previously studied trajectory and accumulated spacing), and the efficiency of capture. Whereas some
aggregates of paramagnetic and diamagnetic particles magnetic patterns designed have been adapted to match strut
flowing past a magnetizable surface [11-13]. However, parameters and spacing of coronary stents, a computational
their studies were based on relatively macroscopic magnetic model provides the ability to investigate a range of pattern
anchor materials. In biological systems, it is frequently not geometries, many of which would not work on current stent
possible to embed macroscopic objects in blood vessel walls, designs.
Prior models by the authors, by contrast, analyze particle Based on model data one can pattern wafers with those
trajectory and aggregate stability attracted to anchors of varied island geometries, and analyze their capture
equivalent physical characteristics (ie. size, shape, magnetic efficiency as well. In that respect, this project has the
properties) as the injected drug-containing magnetic capability to develop the design principles necessary for
particles [17]. Additional two-dimensional computational
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applying the technique to any clinical application which [7] S. Rudge, C. Peterson, C. Vessely, J. Koda, S. Stevens, L. Catterall,
could be aided by magnetic targeting. New stent designs "Adsorption and desorption of chemotherapeutic drugs from a magnetically
and Dendovasclar implantsc tarebeing.used stendconsderd targeted carier (MTC)," J Controlled Release, vol. 74, pp. 335-340, 2001.and endovascular implants are being used and considered
for a wide range of applications outside of coronary stenting, [8] G. A. Flores, "In-vitro blockage of a simulated vascular system using
many of which would have a different set of restrictions on magnetorheological fluids as a cancer therapy," Eur. Cells and Mater., vol.
particle size, magnetic island size and spacing, and flow 3, pp. 9-11, 2002.
velocity. By making the goal of the project the [9] s. P. Vyas, A. Singh, V. Sihorkar, "Ligand-receptor-mediated drug
establishment of relationships between variable parameters delivery: an emerging paradigm in cellular drug targeting," Crit. Rev. Ther.Drug Carrier Syst., vol. 18(1), pp. 1-76, 2001.
and not setting a particular percentage capture yield or
coverage requirement, there is flexibility to examine [10] Y. Xia, G.M. Whitesides, "Soft Lithography," Annu. Rev. Mater. Sci.,
numerous scenarios that can be then fitted to dosage and vol. 28, pp. 153-184,1998.
drug-loading curves for particular pathologies. [I1 ] H. Schewe, M. Takayasu, F.J. Friendlaender, "Observation of Particle
Trajectories in an HGMS Single-Wire System," IEEE Trans. Magn.,
vol .Mag-16, no.1, pp. 149-154. 1980.
V. CONCLUSION [12] F.J. Friedlaender. R. Gerber, W. Kurzl, R.R. Birss, "Particle Motion
Near and Capture on Single Spheres in HGMS," IEEE Trans. Magn., vol.
Flow experiments have thus far confirmed Mag-17, no. 6, pp..2801-2803
computational model predictions on the capability to capture
superparamagnetic particles at small to moderate diameters [13] FJ Fredlaender, R Gerber, HP Henkel, R.R. Birss, "Particle
.,~. , . .Buildup on Single Spheres in HGMS," IEEE Trans. Magn., vol. Mag-17,
without the reliance on large external magnetic gradients to no. 6, pp..2804-2806.
direct particles to a site. Other experiments in progress
involve capture on directly patterned surface in the presence [14] P. A. Voltairas, D. I. Fotiadis, L. K. Michalis, "Hydrodynamics of
of cellular monolayers, in order to evaluate interactions magnetic drug targeting," vol. 35(6), pp. 813-821, June 2002.
between cells, particles, and magnetic substrates. Particles [15] G. Segre and A. Silberberg, "Behaviour of macroscopic rigid spheres
will also be labeled with gene vectors to evaluate the in Poiseuille flow Part I & 2," J. Fluid Mech., vol. 14, pp 115-157, 1962.
capability to successfully transfer molecules from particles 16] F.A. Loweinheim. Electroplating. New York: McGraw-Hill.
across cell membranes lti
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to Targeted Drug Delivery Based on Uniform Magnetic Fields." IEEE
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